Related Experiment Video

Updated: Aug 19, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Novel therapeutics for chemotherapy-resistant acute myeloid leukaemia

A E Frankel1, M W Schuster, J G Jurcic

  • 1Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|July 5, 2001
PubMed

Insights

New targeted therapies show promise for acute myeloid leukemia (AML) patients resistant to chemotherapy. This review details agents targeting cell surface molecules and signaling pathways, aiding rational treatment selection.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Chemotherapy-resistant acute myeloid leukemia (AML) presents a significant clinical challenge with limited curative options.
  • Non-allogeneic transplant therapies offer infrequent cures for refractory AML.
  • A need exists for tools to guide rational selection of novel agents and clinical trials for AML.

Purpose of the Study:

  • To review the properties and initial clinical activity of emerging investigational agents for chemotherapy-resistant AML.
  • To provide an overview of targeted therapeutics acting on cell surface molecules or signal pathway intermediates.
  • To inform drug and clinical trial selection for patients with refractory AML.

Main Methods:

  • Literature review of investigational agents for AML.
  • Description of chemical and biological properties of selected agents.
  • Summary of initial clinical activity data for these agents.

Main Results:

  • Several novel agents targeting CD33, CD45, granulocyte-macrophage colony-stimulating factor receptor, Bcl2, farnesyl transferase, and protein kinase C are under investigation.
  • These agents exhibit diverse mechanisms of action, including antibody conjugates, fusion proteins, oligonucleotides, and enzyme inhibitors/agonists.
  • Initial clinical data highlight the potential of these targeted therapies in refractory AML.

Conclusions:

  • The development of molecularly targeted therapeutics offers new hope for patients with chemotherapy-resistant AML.
  • Selecting appropriate patients for specific targeted therapies and optimizing combination strategies are critical challenges for the future.
  • Further research is needed to refine patient selection and combination regimens for these novel AML treatments.

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...